2024
DOI: 10.1007/s13555-024-01292-z
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study

Richard B. Warren,
Lev Pavlovsky,
Antonio Costanzo
et al.
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 43 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?